ClinicalTrials.gg
RecruitingNCT06301581Updated Nov 5, 2026

Retrospective Analysis of Speech Performance Using the HiRes Ultra and HiRes Ultra 3D Cochlear Implant

An observational study in Cochlear Hearing Loss, sponsored by Advanced Bionics AG. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Advanced Bionics AG (part of Sonova AG) · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Nov 5, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Hearing Loss, Sensorineural by Sonova AG — 4 open to participants now, 4 under way, none of them phase 3. Hearing Loss, Sensorineural · Sonova AG.

Started
2024
with 2 others
Observational
7 of 28
2 open now
Registered
25th of 28
by date

Among the 28 studies in Hearing Loss, Sensorineural by Sonova AG, this one is one of 3 that started in 2024, is one of 7 observational ones, and was the 25th registered.

Hearing Loss, Sensorineural

348 studies on the registry are indexed under Hearing Loss, Sensorineural; 103 are open to participants now.

Browse Hearing Loss, Sensorineural studies →

Open to participants now

4 of the 28 studies in Hearing Loss, Sensorineural by Sonova AG are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 70 Hearing Loss, Sensorineural studies recruiting now, 39 (56%) set no upper age limit and 19 (27%) stop at 75 or younger; 26 take children under 18; 17 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Hearing Loss, Sensorineural by Sonova AG, or all of them as a file.
02

Study summary

This is a retrospective study designed to collect speech perception results for HiRes Ultra CI and HiRes Ultra 3D CI users as measured in the clinical routine and to confirm the performance of these devices.

03

Conditions studied

  • Cochlear Hearing Loss
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The studied population consists of all CI users implanted with a HiRes Ultra Version V2 or HiRes Ultra 3D Version V2 CI at the Medical University of Hannover in Germany (MHH).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unilateral or bilateral HiRes Ultra CI or HiRes Ultra 3D CI users including

    • Ultra Version V2 newly implanted on this side (Group 1)
    • Ultra Version V2 users implanted following an Ultra Version V1 device failure in the same ear (Group 2)
  • signed

Exclusion criteria

Exclusion Criteria:

  • no exclusion criteria
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1

    HiRes Ultra or HiRes Ultra 3D Version V2 newly implanted on this side

  • Group 2

    HiRes Ultra or HiRes Ultra 3D Version V2 implanted following an Ultra Version V1 device failure on the same ear

06

What researchers measure

Primary outcomes

  1. Freiburger monosyllabic word recognition score in quiet in the implanted ear

    Score obtained with the Freiburger Monosyllabic word test

    Time frame: 12 months after device activation

07

Study locations

1 of 1 sites recruiting
  • Medizinische Hochschule Hannover
    Hanover, D-30625, Germany
    Recruiting
    • Andreas Büchner · Contact
    • Andreas Büchner · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2025 → Dec 2027 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2024
First posted
Mar 8, 2024
StartActual
Jan 22, 2024
Primary completionEst.
Dec 2027was Dec 2025
CompletionEst.
Dec 2027was Dec 2025
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Medizinische Hochschule Hannover · Hanover, Germany
Show 1 removed
  • Medizinische Hochschule Hannover · Hannover, Germany
Nov 5, 2026
Primary completion
Dec 2025→Dec 2027
Nov 5, 2026
Study completion
Dec 2025→Dec 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    1 site added, 1 site removed
    Show site
    • Medizinische Hochschule Hannover · Hanover, Germany
    Show 1 removed
    • Medizinische Hochschule Hannover · Hannover, Germany
    Primary completion Dec 2025→Dec 2027
    Study completion Dec 2025→Dec 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06301581
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
Jan 22, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Andreas Büchner, Prof
Contact
buechner.andreas@mh-hannover.de
49 511 532 8589
Kliesch Sven
Contact
Kliesch.Sven@mh-hannover.de
49 511 532 8069
Andreas Büchner
principal investigator · Hannover Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion